A Third COVID-19 Booster Is Important
Twenty
different COVID-19 variants were effectively identified and neutralised after a
third booster, according to the new study for which the University of Surrey
provided the crucial antigenic map of variants of concern.
From: University of Surrey
July 25, 2022 -- While
the study's results suggested that immunity decreases 20 weeks after
vaccination, a third booster (of the Pfizer-BioNTech vaccine, in the case of
this study) helped the immune system to identify and neutralise the 20
different variants.
The antigenic map
allowed the team to identify and measure how each variant impacted the immune
system.
Dr Daniel Horton,
co-author of the study and Reader in Veterinary Virology at the University of
Surrey, said:
"The emergence of
this disease and its disruptive and deadly impact on our day-to-day lives
demonstrates how crucial it is for the scientific community to work together to
identify and characterise infectious diseases quickly.
"The University of
Surrey's contribution to this study through the mapping of the various variants
is itself part of a landmark €90 million collaborative effort to tackle
zoonotic diseases in Europe, reflecting our focus on understanding the
inextricable links between the health of animals, humans and, indeed, the
planet we all share."
The Pirbright Institute
led this collaborative study with scientists from the University of Surrey,
Imperial College in London and the UK Health Security Agency (UKHSA) to
understand the immune response of individuals aged 70-89 who had received the
Pfizer-BioNTech vaccine.
This vaccine works by
triggering the immune system to create Y-shaped proteins, known as antibodies,
that can stick to the spike proteins which are found on the surface of the
coronavirus. If a person is infected with SARS-CoV-2, the antibodies bind the
spike proteins preventing the virus from attaching to and entering the human
cell, therefore helping to protect from severe disease. Antibodies also act as
a beacon to alert the immune system to help fight the infection.
Dr Dalan Bailey, Head
of the Viral Glycoproteins group at Pirbright, said:
"Understanding how
the levels of neutralising antibodies relate to a well-defined immune response
will be an important step in understanding how the immune system responds to
SARS-CoV-2 and could also help in the management of Covid-19.
"This information
could help us to understand whether the risk of breakthrough infections,
hospitalisation and death is increased by waning immunity or new variants.
Research comparing immune responses to different SARS-CoV-2 variants and
understanding the role of different mutations is vital in the management of the
Covid-19 pandemic and in predicting the outcome of new variants."
The research was
published in Nature Microbiology.
https://www.sciencedaily.com/releases/2022/07/220725105556.htm
No comments:
Post a Comment